{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:06:26Z","timestamp":1790856386209,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Rapid symptom relief is an important consideration for patients with ulcerative colitis (UC) experiencing a flare. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. We evaluated patient-reported symptomatic improvement from patients in the ELEVATE UC program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was a post-hoc analysis of pooled daily e-diary data from patients with moderately to severely active UC receiving etrasimod or placebo in the phase III ELEVATE UC 52 and ELEVATE UC 12 trials. During the 12-week induction periods, patients self-reported stool frequency and rectal bleeding on days 1-28. Daily symptomatic response and symptomatic remission were calculated (partial modified Mayo Score).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 787 patients (527 receiving etrasimod, 260 placebo) were included in the analysis. Etrasimod-treated patients had statistically significantly higher rates of symptomatic response and symptomatic remission during the first 28\u2009days of therapy, with adjusted differences (95% CIs) reaching statistical significance from day 2 (5.6% [0.8-10.3], P\u2009=\u2009.022) to day 11 (4.7% [0.4-9.0], P\u2009=\u2009.034), respectively. In patients na\u00efve to biologic\/Janus kinase inhibitor therapy, symptomatic response was statistically significantly improved with etrasimod vs placebo from day 3 (8.9% [2.3-15.5], P\u2009=\u2009.008). Symptomatic improvement rates were similar with and without concomitant corticosteroid use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this post-hoc analysis, improvements in UC symptoms occurred in patients receiving etrasimod vs placebo from as early as day 2. These findings indicate a rapid onset of symptomatic effect with etrasimod treatment for moderately to severely active UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov numbers<\/jats:title>\n                    <jats:p>NCT03945188, NCT03996369.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf333","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T12:45:02Z","timestamp":1767185102000},"page":"1075-1085","source":"Crossref","is-referenced-by-count":2,"title":["Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-5795","authenticated-orcid":false,"given":"Marla C","family":"Dubinsky","sequence":"first","affiliation":[{"name":"Department of Medicine and Pediatrics, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-4242","authenticated-orcid":false,"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) Gastroenterology Unit, , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0972-8148","authenticated-orcid":false,"given":"Peter M","family":"Irving","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas\u2019 National Health Service Foundation Trust IBD Unit, , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hur","sequence":"additional","affiliation":[{"name":"Pfizer Inc HTA, Value & Evidence, , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sidhu","sequence":"additional","affiliation":[{"name":"Pfizer Inc Global Medical Affairs, , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Woolcott","sequence":"additional","affiliation":[{"name":"Pfizer Inc Global Medical Affairs, , Collegeville, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Wang","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Collegeville, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Goetsch","sequence":"additional","affiliation":[{"name":"Pfizer AG I&I Research and Development, , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2895-5821","authenticated-orcid":false,"given":"Joana","family":"Torres","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hospital Beatriz \u00c2ngelo , Loures, Lisbon,","place":["Portugal"]},{"name":"Division of Gastroenterology, Hospital da Luz , Lisbon,","place":["Portugal"]},{"name":"Faculty of Medicine, University of Lisbon , Lisbon,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"University of Calgary Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, , Calgary, AB,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,8]]},"reference":[{"key":"2026060322322037500_izaf333-B1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12876-020-1164-0","article-title":"The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe","volume":"20","author":"Armuzzi","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"2026060322322037500_izaf333-B2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000505092","article-title":"Ulcerative colitis: disease burden, impact on daily life, and reluctance to consult medical professionals: results from a Japanese internet survey","volume":"5","author":"Hibi","year":"2020","journal-title":"Inflamm Intest Dis"},{"key":"2026060322322037500_izaf333-B3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2026060322322037500_izaf333-B4","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/ibd\/izae229","article-title":"Health-related quality of life outcomes with etrasimod treatment in patients with ulcerative colitis: a post hoc analysis of data from ELEVATE UC 52 and ELEVATE UC 12","volume":"31","author":"Armuzzi","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026060322322037500_izaf333-B5","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"2026060322322037500_izaf333-B6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026060322322037500_izaf333-B7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/ecco-jcc\/jjac145","article-title":"What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study","volume":"17","author":"Schoefs","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026060322322037500_izaf333-B8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2147\/PPA.S152872","article-title":"Inflammatory bowel disease patients prioritize mucosal healing, symptom control, and pain when choosing therapies: results of a prospective cross-sectional willingness-to-pay study","volume":"12","author":"Gregor","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"2026060322322037500_izaf333-B9","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/j.1365-2036.2009.03972.x","article-title":"Treatment of ulcerative colitis from the patient\u2019s perspective: a survey of preferences and satisfaction with therapy","volume":"29","author":"Gray","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2026060322322037500_izaf333-B10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.dld.2016.01.013","article-title":"Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study","volume":"48","author":"Peyrin-Biroulet","year":"2016","journal-title":"Dig Liver Dis"},{"key":"2026060322322037500_izaf333-B11","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026060322322037500_izaf333-B12","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.3748\/wjg.v23.i35.6385","article-title":"Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?","volume":"23","author":"Vasudevan","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2026060322322037500_izaf333-B13","year":"2024"},{"key":"2026060322322037500_izaf333-B14","year":"2024"},{"key":"2026060322322037500_izaf333-B15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"2026060322322037500_izaf333-B16","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/ecco-jcc\/jjae079","article-title":"Impact of prior biologic or Janus kinase inhibitor therapy on efficacy and safety of etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 trials","volume":"18","author":"Vermeire","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026060322322037500_izaf333-B17","doi-asserted-by":"publisher","first-page":"jjae150","DOI":"10.1093\/ecco-jcc\/jjae150","article-title":"Etrasimod corticosteroid-free efficacy, impact of concomitant corticosteroids on efficacy and safety, and corticosteroid-sparing effect in ulcerative colitis: analyses of the ELEVATE UC clinical programme","volume":"19","author":"Sands","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026060322322037500_izaf333-B18","author":"US Department of Health and Human Services Food and Drug Administration","year":"2022"},{"key":"2026060322322037500_izaf333-B19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.14309\/ajg.0000000000001979","article-title":"Rapid and sustained symptom relief in patients with ulcerative colitis treated with filgotinib: data from the phase 2b\/3 SELECTION trial","volume":"118","author":"Danese","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026060322322037500_izaf333-B20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026060322322037500_izaf333-B21","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as Day 1 of induction treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026060322322037500_izaf333-B22","doi-asserted-by":"publisher","first-page":"101866","DOI":"10.1016\/j.eclinm.2023.101866","article-title":"Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"57","author":"Attauabi","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026060322322037500_izaf333-B23","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1093\/ibd\/izae288","article-title":"Etrasimod as a monotherapy or with concomitant use of corticosteroids and\/or aminosalicylates: results from the ELEVATE UC clinical program","volume":"31","author":"Yarur","year":"2025","journal-title":"Inflamm Bowel Dis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/6\/1075\/66803780\/izaf333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/6\/1075\/66803780\/izaf333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:32:39Z","timestamp":1780540359000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/6\/1075\/8467083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,8]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf333","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,2,8]]}}}